Publication | Open Access

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2

Breast OncologyOncologyMedicineBreast CancerCancer TreatmentPharmacologyRadiation OncologyEndocrine-related CancerOverall Survival Results